Mineralys Therapeutics, Inc. Income Statement
MLYS / Health Care|3 years of annual SEC 10-K data (FY2022-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| SG&A Expense | $23.8M | $14.3M | $5.2M |
| R&D Expense | $168.6M | $70.4M | $26.3M |
| Operating Income | -$192.4M | -$84.7M | -$31.5M |
| Net Income | -$177.8M | -$71.9M | -$29.8M |
| EPS (Basic) | -$3.66 | -$1.99 | -$5.77 |
| EPS (Diluted) | -$3.66 | -$1.99 | -$5.77 |
| Shares Outstanding | 48.5M | 36.2M | 5.2M |